Search
Organon & Co
OGNAdd to Watchlist
13.430USD
+0.005+0.04%
Close 06/18, 16:00（ET）Quotes delayed by 15 min
3.53BMarket Cap
14.23P/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-18The current earnings forecast score of Organon & Co is 5.67, ranking 140 out of 157 in the Pharmaceuticals industry. The average price target is 9.00, with a high of 12.00 and a low of 5.00.
Analyst Rating
Based on
6
analysts
Hold
Current Rating
10.800
Target Price
-19.58%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
175
Total
6
Median
8
Average
Company name
Ratings
Analysts
Organon & Co
OGN
6
Amgen Inc
AMGN
38
Biogen Inc
BIIB
38
Eli Lilly and Co
LLY
35
AbbVie Inc
ABBV
34
Vertex Pharmaceuticals Inc
VRTX
34
1
2
3
...
35
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is Organon & Co's expected revenue for the next quarter?
Organon & Co's expected revenue is 1.57B.
What is Organon & Co's price target?
Analysts forecast that Organon & Co's price target is USD 9.00, with the highest forecast at USD 12.00 and the lowest forecast at USD 5.00.
How have Organon & CoOGN's recent earnings per share performed?
The market expectation was USD 0.56, while Organon & CoOGN's earnings per share (EPS) for the previous quarter was USD -0.79. EPS for the next quarter is expected at USD 0.92.
What is the analyst rating for Organon & Co?
Based on the ratings of Organon & Co's stock from 6 analysts, most analysts support a signal_hold trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as signal_hold. Please note that this is not trading advice. You still need to conduct your own analysis.
